Pathwork Diagnostics Investors

16 investors on Angel Roster list Pathwork Diagnostics in their portfolio. Most are venture capital firms and private equity firms, the most common stage is Series B and the largest groups are based in the United States and the United Kingdom.

Investors are matched on the company name in their portfolio, so companies that share the name Pathwork Diagnostics can appear together.

Investors listed
16
With verified email
38%
Most common stage
Series B
Top location
United States

Updated October 13, 2026 · How we compile this data

Top 16 Pathwork Diagnostics investors

The most complete profiles first. Showing 16 of 16.

  • Ken HaasVerified

    Venture Capital, Advisor, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Peter BainesVerified

    Venture Capital, Investor · United Kingdom

    SeedHealth CareE-commerceCybersecurityDeepTech

    Portfolio: Catalyst Biosciences, Vitrue, Am-Beo, Thiakis and 53 more

    Verified email available

  • andrew sinclairVerified

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • David SchnellVerified

    Venture Capital · United States

    Health CareWearablesGeneticsBiotechnology

    Portfolio: Rejuvenon, Gloucester Pharmaceuticals, Visiogen, NGM Biopharmaceuticals and 40 more

    Verified email available

  • Shelley ChuVerified

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Tim HainesVerified

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Verified email available

  • Bali Muralidhar

    Venture Capital, Private Equity Firm, Investor · United Kingdom

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 69 more

    Contact details available

  • Brian Gallagher, Jr.

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Aileron Therapeutics, Amarin and 67 more

    Contact details available

  • Kurt von Emster

    Venture Capital, Private Equity Firm, Investor · United States

    Series BHealth CareWomen FoundedInvestment ManagementLife Science

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Pete Hudson, M.D.

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareHospitalsGeneticsWomen Founded

    Portfolio: Lassen Therapeutics, Avid Radiopharmaceuticals, Nereus Pharmaceuticals, Calistoga Pharmaceuticals and 59 more

    Contact details available

  • Vin Miles

    Venture Capital, Investor · United States

    Series BHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Bob More

    Venture Capital · United States

    Health CareGeneticsWomen FoundedLife Science

    Portfolio: Lassen Therapeutics, Avid Radiopharmaceuticals, Nereus Pharmaceuticals, Calistoga Pharmaceuticals and 59 more

    Contact details available

  • John Heard

    Venture Capital, Private Equity Firm · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Russell Hirsch

    Venture Capital · United States

    Health CareWearablesGeneticsBiotechnology

    Portfolio: Rejuvenon, Gloucester Pharmaceuticals, Visiogen, NGM Biopharmaceuticals and 40 more

    Contact details available

  • Sarah Shackelton

    Venture Capital · United Kingdom

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more

    Contact details available

  • Ted Driscoll

    Angel/Individual, Investor · United States

    Life ScienceMobileClean TechnologyConsumer Internet

    Portfolio: Tibion Bionic Technologies, NuMedii, Fluxion Biosciences, Zipline Medical and 15 more

    Contact details available

By investment stage

By location

Related industries

Most-backed portfolio companies

Frequently asked questions

How many Pathwork Diagnostics investors are on Angel Roster?

Angel Roster lists 16 Pathwork Diagnostics investors. 6 of them (38%) include a verified email address.

What types of investors are they?

The most common investor types are Venture Capital Firms (15), Private Equity Firms (5) and Angel Investors (1). An investor can have more than one type, for example an angel who is also a venture partner.

Which stages do Pathwork Diagnostics investors invest in?

Among those that list a stage, the most common are Series B (6) and Seed (2).

Where are Pathwork Diagnostics investors based?

Most are based in the United States (10) and the United Kingdom (6).

Which companies have Pathwork Diagnostics investors backed?

The most-backed portfolio companies among them are Portola Pharmaceuticals (14), Algeta (11), Avila Therapeutics (11), Oxagen (11) and Lombard Medical plc (10).

How do I contact Pathwork Diagnostics investors?

Create a free Angel Roster account to search and filter all 16, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.